Clinical Trial Update: A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing zanubrutinib (BGB-3111) with ibrutinib in Waldenström's macroglobulinemia. The study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: BeiGene | Conditions: Waldenström's Macroglobulinemia | Phase 3 | Status: COMPLETED | Results posted: 2023-06-09